The meeting will cover the design and optimisation of agents targeting a variety of cancer mechanisms. Individual case studies will examine approaches to oncology drug discovery in areas which will include Hsp90 inhibition, HDAC inhibition, PI3 kinase inhibition and estrogen receptor downregulators.